RU2014153760A - Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение - Google Patents
Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение Download PDFInfo
- Publication number
- RU2014153760A RU2014153760A RU2014153760A RU2014153760A RU2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- peptide
- composition according
- paragraphs
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 34
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 16
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 239000003349 gelling agent Substances 0.000 claims abstract 7
- 229920000570 polyether Polymers 0.000 claims abstract 6
- 229920005862 polyol Polymers 0.000 claims abstract 6
- 150000003077 polyols Chemical class 0.000 claims abstract 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract 4
- 102000004378 Melanocortin Receptors Human genes 0.000 claims abstract 4
- 108090000950 Melanocortin Receptors Proteins 0.000 claims abstract 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract 4
- 239000003446 ligand Substances 0.000 claims abstract 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 3
- 108010008364 Melanocortins Proteins 0.000 claims abstract 2
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims abstract 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000002865 melanocortin Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12290189.5 | 2012-06-08 | ||
| EP12290189.5A EP2705835A1 (en) | 2012-06-08 | 2012-06-08 | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| PCT/EP2013/061732 WO2013182653A1 (en) | 2012-06-08 | 2013-06-06 | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014153760A true RU2014153760A (ru) | 2016-08-10 |
Family
ID=48577065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014153760A RU2014153760A (ru) | 2012-06-08 | 2013-06-06 | Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20150157719A1 (enExample) |
| EP (2) | EP2705835A1 (enExample) |
| JP (1) | JP2015518873A (enExample) |
| CN (1) | CN104487049A (enExample) |
| HK (1) | HK1208171A1 (enExample) |
| RU (1) | RU2014153760A (enExample) |
| WO (1) | WO2013182653A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3301962A1 (en) | 2011-12-29 | 2026-03-02 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
| US10196425B2 (en) | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| PT2970389T (pt) | 2013-03-15 | 2020-10-21 | Rhythm Pharmaceuticals Inc | Composições farmacêuticas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI331922B (en) * | 2002-08-09 | 2010-10-21 | Ipsen Pharma Sas | Growth hormone releasing peptides |
| KR100997177B1 (ko) | 2005-07-08 | 2010-11-29 | 입센 파마 에스.에이.에스 | 멜라노코르틴 수용체 리간드 |
| CA2665101A1 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and it's process of preparation |
| EP2148692B1 (en) | 2007-05-25 | 2017-01-25 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| TW200916113A (en) * | 2007-08-08 | 2009-04-16 | Sod Conseils Rech Applic | Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue |
| WO2009120656A1 (en) * | 2008-03-24 | 2009-10-01 | Palatin Technologies, Inc. | Pharmaceutical for ocular indications |
| US9314509B2 (en) * | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
-
2012
- 2012-06-08 EP EP12290189.5A patent/EP2705835A1/en not_active Withdrawn
-
2013
- 2013-06-06 CN CN201380029769.XA patent/CN104487049A/zh active Pending
- 2013-06-06 EP EP13727192.0A patent/EP2858626A1/en not_active Withdrawn
- 2013-06-06 JP JP2015515528A patent/JP2015518873A/ja not_active Abandoned
- 2013-06-06 WO PCT/EP2013/061732 patent/WO2013182653A1/en not_active Ceased
- 2013-06-06 HK HK15108823.9A patent/HK1208171A1/xx unknown
- 2013-06-06 RU RU2014153760A patent/RU2014153760A/ru not_active Application Discontinuation
- 2013-06-13 US US14/406,287 patent/US20150157719A1/en not_active Abandoned
-
2016
- 2016-09-22 US US15/272,662 patent/US20170035884A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170035884A1 (en) | 2017-02-09 |
| US20150157719A1 (en) | 2015-06-11 |
| CN104487049A (zh) | 2015-04-01 |
| WO2013182653A1 (en) | 2013-12-12 |
| JP2015518873A (ja) | 2015-07-06 |
| EP2705835A1 (en) | 2014-03-12 |
| HK1208171A1 (en) | 2016-02-26 |
| EP2858626A1 (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6680640A2 (es) | Uso de aglutinantes para fabircar formulaciones estables al almacenamiento | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| NZ604026A (en) | Injectable flowable composition comprising buprenorphine | |
| RU2015137145A (ru) | Новые жидкие композиции с повышенной стабильностью | |
| BRPI0514297A (pt) | composições farmacêuticas para liberação controlada de compostos biologicamente ativos | |
| NZ602392A (en) | Stable bortezomib formulations | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| PE20141671A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| IN2015DN02328A (enExample) | ||
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| EA200970348A1 (ru) | Новые инъецируемые депо-композиции и способ получения таких композиций | |
| EA201492292A1 (ru) | Препарат антител | |
| UA104945C2 (uk) | Фармацевтична композиція лігандів рецепторів секретагогів гормону росту | |
| WO2012168885A3 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| PE20091949A1 (es) | Formulacion farmaceutica solida con liberacion retardada | |
| WO2013006743A3 (en) | Personal care compositions with improved solubility of a solid cosmetic active substance | |
| MY175309A (en) | Pharmaceutical composition useful for adhesion prevention or hemostasis | |
| MX2017013244A (es) | Dentifricos a base de calcio para una mejor absorcion de los ingredientes activos. | |
| JP2018154613A5 (enExample) | ||
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
| MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. | |
| EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
| MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
| JP2015518873A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170814 |